WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Ra Capital Management, Llc bought 423,398 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were bought at an average cost of $23.34 per share, for a total transaction of $9,882,109.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

WAVE Life Sciences Ltd. (NASDAQ:WVE) traded down $0.10 on Wednesday, hitting $24.75. 146,300 shares of the company were exchanged, compared to its average volume of 97,742. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.50 and a current ratio of 11.50. WAVE Life Sciences Ltd. has a one year low of $15.15 and a one year high of $40.15.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.03. WAVE Life Sciences had a negative net margin of 3,338.68% and a negative return on equity of 59.52%. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.77 million. equities research analysts predict that WAVE Life Sciences Ltd. will post -3.8 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Ra Capital Management, Llc Purchases 423,398 Shares of WAVE Life Sciences Ltd. (WVE) Stock” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/11/15/ra-capital-management-llc-purchases-423398-shares-of-wave-life-sciences-ltd-wve-stock.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. American International Group Inc. increased its holdings in WAVE Life Sciences by 7.1% during the first quarter. American International Group Inc. now owns 4,554 shares of the company’s stock worth $125,000 after buying an additional 302 shares during the last quarter. Nationwide Fund Advisors increased its holdings in WAVE Life Sciences by 58.1% during the second quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock worth $125,000 after buying an additional 2,470 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in WAVE Life Sciences by 71.0% during the second quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock worth $175,000 after buying an additional 3,912 shares during the last quarter. Strs Ohio increased its holdings in WAVE Life Sciences by 6.3% during the second quarter. Strs Ohio now owns 11,900 shares of the company’s stock worth $221,000 after buying an additional 700 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in WAVE Life Sciences by 62.3% during the second quarter. Rhumbline Advisers now owns 12,502 shares of the company’s stock worth $233,000 after buying an additional 4,800 shares during the last quarter. Institutional investors and hedge funds own 69.53% of the company’s stock.

A number of research analysts have weighed in on the stock. Zacks Investment Research lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Mizuho set a $34.00 price objective on shares of WAVE Life Sciences and gave the company a “buy” rating in a research note on Saturday, October 21st. BidaskClub lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 28th. Leerink Swann reaffirmed an “outperform” rating and issued a $53.00 price objective (up from $42.00) on shares of WAVE Life Sciences in a research note on Wednesday. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $40.00 price objective (down from $42.00) on shares of WAVE Life Sciences in a research note on Thursday, August 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. WAVE Life Sciences has a consensus rating of “Buy” and an average price target of $41.60.

About WAVE Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.